FDA greenlights Abbott's blood glucose test strips

Kaitlyn Dmyterko | | Health Imaging | Screening
The FDA has granted Abbott Diabetes Care 510(k) clearance for its FreeStyle Lite blood glucose test strips, which minimize interference by using a GDH-FAD enzyme that is unaffected by non-glucose sugars.

The Alameda, Calif.-based company said that standard test strips utilize the GDH-PQQ enzyme, which has the potential to be affected by non-glucose sugars maltose or galactose and could interfere with testing. According to Abbott, the test trips are compatible with FreeStyle Lite blood glucose monitoring systems.

Abbott said that the FreeStyle Lite test strips will ship to customers in July and will be widely available in August.

Kaitlyn Dmyterko

Related Content

Rising rates of interval breast cancers have experts calling for more risk-based screenings
Rates of breast cancer diagnosis, death expected to climb in coming decades
AI quantifies breast arterial calcifications on mammograms
AI 'not safe' to be implemented as a solo reader for breast cancer screening exams
American College of Radiology announces significant expansion of Lung Cancer Screening Registry
AI beats standard regression models at predicting lung cancer risk

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.